HSBC/CALL/MODERNA/350/0.1/15.01.25 Stock

DE000HG807R8

Real-time Boerse Frankfurt Warrants 09:20:50 2024-06-03 am EDT
0.07 ^EUR	-20.45%

1 month	+282.61%
3 months	+877.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Chart HSBC/CALL/MODERNA/350/0.1/15.01.25

Latest news about MODERNA, INC.

Moderna, Merck Say 3-Year Data for Melanoma Combination Therapy Show Continued Improvement in Recurrence-Free Survival	09:18am	MT
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says	08:33am	RE
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up	08:00am	RE
RBC Raises Price Target on Moderna to $160 From $135 Amid RSV Vaccine Approval From FDA, Keeps Outperform Rating	06:53am	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.07	-20.45%
24-05-31	0.088	-33.33%
24-05-30	0.132	+13.79%
24-05-29	0.116	-24.68%
24-05-28	0.154	-38.40%

Real-time Boerse Frankfurt Warrants

Last update June 03, 2024 at 09:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	HSBC
WKN	HG807R
ISIN	DE000HG807R8
Date issued	2023-02-02
Strike	350 $
Maturity	2025-01-15 (226 Days)
Parity	10 : 1
Emission price	1.96 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.76 €
Lowest since issue	0.001 €
Spread	0.03 €
Spread %	29.13%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company